Concerned about elevated PSA levels?

An Axumin scan may help

Axumin® (fluciclovine F 18) is an advanced diagnostic imaging agent, or radiotracer, that’s used with a positron emission tomography (PET)/computed tomography (CT) scan for men who have had prior treatment for prostate cancer and now have elevated prostate specific antigen (PSA) levels.

If you have recurrent prostate cancer, your doctor needs to get more accurate information about the location of your disease.

September is Prostate Cancer Awareness Month

At Blue Earth Diagnostics, we develop and provide PET diagnostic imaging radiopharmaceutical products to inform diagnosis and treatment decisions for patients with recurrent prostate cancer. We stand committed to supporting those parts of life that matter most: health and well-being.

September marks Prostate Cancer Awareness Month, a time for raising awareness and taking action to help fight this serious disease that takes the lives of approximately 33,330 U.S. men each year.1

Blue Earth Diagnostics has a strong commitment in prostate cancer, and we are driven to find innovative imaging solutions for men affected by this disease. We work closely with physicians, healthcare professionals and patients to provide access to PET imaging products that can help guide decisions about patient care. Our initial product, Axumin® (fluciclovine F 18) injection, is FDA-approved for PET imaging of prostate cancer recurrence and widely available across the U.S.

At our core, Blue Earth Diagnostics is all about helping patients. We continue to work tirelessly toward that goal so that more men with recurrent prostate cancer can benefit from informed decision making resulting from advanced diagnostic imaging.

1; accessed August 10, 2020

This is not an actual patient.

What is Axumin? 

Axumin® (fluciclovine F 18) injection is a diagnostic imaging agent (sometimes called a radiotracer). Axumin is used along with a positron emission tomography (PET) imaging scan for men who have had prior treatment for prostate cancer and now have prostate specific antigen (PSA) levels that are elevated.


What do I need to know about Axumin?

  • As with all diagnostic imaging tests such as x-rays, bone scans and computed tomography (CT) scans, it is possible that the physician (a radiologist or nuclear medicine physician) that reviews your Axumin PET/CT scan can interpret your results incorrectly. This means that a negative Axumin PET/CT scan does not rule out that you have recurrent prostate cancer, and a positive Axumin PET/CT scan does not confirm that you have recurrent prostate cancer.
  • How well Axumin works seems to be affected by PSA levels. As PSA levels go up, an Axumin PET/CT scan is better able to identify recurrent prostate cancer.
  • Serious reactions including anaphylaxis, a severe, potentially life-threatening allergic reaction, may occur in patients who receive Axumin.
  • Axumin adds to your long-term overall radiation exposure, which can lead to an increased risk of cancer.

What are the possible side effects of Axumin?

Most commonly reported adverse reactions are:

  • Injection site pain
  • Injection site redness
  • Unusual taste in the mouth

Tell your doctor if you have any side effect that bothers you or does not go away.

These are not all the possible side effects of Axumin. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.